Supplementary Data — Bebtelovimab for COVID-19: real-time meta-analysis of 6 studies

@CovidAnalysis, October 2026, Version 16V16 (V1 2022)
c19early.org
October 2026

Bebtelovimab COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Lilly (RCT)−151%2.51 · 0.10–61.14death1/2520/128 Lilly (RCT)−201%3.01 · 0.12–73.15death1/1270/128 Lilly (RCT)−27%1.27 · 0.25–6.46hosp.5/2522/128 Lilly (RCT)−51%1.51 · 0.26–8.90hosp.3/1272/128 Lilly (RCT)−2%1.02 · 0.15–7.16hosp.2/1252/128 Lilly (RCT)36%0.64 · 0.40–1.03viral+33/25226/128 Lilly (RCT)38%0.62 · 0.35–1.10viral+16/12726/128 Lilly (RCT)33%0.67 · 0.38–1.17viral+17/12526/128 Dougan (RCT)−27%1.27 · 0.25–6.46hosp.5/2522/128BLAZE-4 Dougan (RCT)−2%1.02 · 0.15–7.16hosp.2/1252/128BLAZE-4 Dougan (RCT)4%0.96 · 0.95–0.97viral load125 (n)128 (n)BLAZE-4 Dougan (RCT)30%0.70 · 0.63–0.78viral load125 (n)128 (n)BLAZE-4 Dougan (RCT)15%0.85 · 0.81–0.88viral load125 (n)128 (n)BLAZE-4 Dougan (RCT)39%0.61 · 0.34–1.11viral+15/12525/128BLAZE-4 Dryden-Peterson86%0.14 · 0.01–2.76death0/3773/377 Dryden-Peterson43%0.57 · 0.28–1.19death/hosp.10/37717/377 Dryden-Peterson29%0.71 · 0.32–1.59hosp.10/37714/377 Kip20%0.80 · 0.32–2.02death/hosp.6/15715/314 Molina (PSM)57%0.43 · 0.11–1.30death3/3,73911/5,423 Molina59%0.41 · 0.17–1.03ICU6/3,73921/5,423 Molina (PSM)56%0.44 · 0.30–0.64hosp.38/3,739107/5,423 Molina (PSM)46%0.54 · 0.38–0.74hosp.48/3,739116/5,423 Molina (PSM)−33%1.33 · 1.12–1.57progression260/3,739275/5,423 Sridhara (PSM)86%0.14 · 0.01–2.76death0/1,0913/1,091 Sridhara (PSM)25%0.75 · 0.43–1.31death/hosp.24/1,09128/1,091 Sridhara (PSM)11%0.89 · 0.52–1.53hosp.24/1,09127/1,091
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Bebtelovimab
reduces riskBebtelovimab
increases risk →
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.